十一酸诺龙 | 862-89-5

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 十一酸诺龙
• 英文名称: Nandrolone undecylate
• 英文别名: [(8R,9S,10R,13S,14S,17S)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] undecanoate
• CAS: 862-89-5
• 化学式: C₂₉H₄₆O₃
• mdl: MFCD09951795
• 分子量: 442.7
• InChiKey: GRAAWEGTURLYKP-MVTMSODMSA-N

物化性质

• 沸点：
  513.23°C (rough estimate)
• 密度：
  0.9542 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  32
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.862
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S22,S36
• 危险类别码：
  R20/21/22,R40

文献信息

• [EN] SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF<br/>[FR] LIGANDS DE SARD - COMPOSÉS DE DÉGRADATION SÉLECTIFS DE RÉCEPTEURS DES ANDROGÈNES - ET MÉTHODES D'UTILISATION
  申请人：UNIV TENNESSEE RES FOUND

  公开号：WO2017214634A1

  公开（公告）日：2017-12-14

  This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

  该发明涉及吡咯、吡唑、咪唑、三唑和吗啉基选择性雄激素受体降解剂（SARD）化合物，包括含有杂环苯胺环的合成前体、R-异构体以及非羟基化和/或非手性的丙酰胺，以及在治疗前列腺癌、晚期前列腺癌、去势耐药性前列腺癌、三阴性乳腺癌、其他表达雄激素受体的癌症、雄激素性脱发或其他高雄激素皮肤疾病、肯尼迪病、肌萎缩性侧索硬化（ALS）、腹主动脉瘤和子宫肌瘤等方面的制药组合物和用途，以及用于降低受试者中雄激素受体全长（AR-FL）的水平，包括致病性或耐药突变、AR-剪接变体（AR-SV）和AR的致病性多谷氨酸（polyQ）多态性的方法。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT D'UNE INFLAMMATION
  申请人：RESOLVYX PHARMACEUTICALS INC

  公开号：WO2010120719A1

  公开（公告）日：2010-10-21

  The invention relates to novel resolvin compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel resolvin compounds of the invention.

  这项发明涉及新型利用新型resolvin化合物和其药物制剂的治疗方法。
• [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSÉS THÉRAPEUTIQUES
  申请人：RESOLVYX PHARMACEUTICALS INC

  公开号：WO2010039531A1

  公开（公告）日：2010-04-08

  The invention relates to novel resolvin compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel resolvin compounds of the invention.

  这项发明涉及新型resolvin化合物及其制药制剂。该发明还涉及使用该发明的新型resolvin化合物进行治疗的方法。
• [EN] FULVESTRANT FORMULATION<br/>[FR] PREPARATION DE FULVESTRANT
  申请人：ASTRAZENECA AB

  公开号：WO2001051056A1

  公开（公告）日：2001-07-19

  The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol, more particularly to a formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.

  本发明涉及一种新型的持续释放药物制剂，适用于注射给药，含有化合物7α-[9-(4,4,5,5,5-五氟戊基磺酰基)壬基]雌-1,3,5(10)-三烯-3,17β-二醇，更具体地说，本发明涉及一种适用于注射给药的制剂，该制剂含有化合物7α-[9-(4,4,5,5,5-五氟戊基磺酰基)壬基]雌-1,3,5(10)-三烯-3,17β-二醇在蓖麻油酸酯载体中的溶液，该载体还包括至少一种醇和一种能在蓖麻油酸酯载体中溶解的非水酯溶剂。
• Drug combination pharmaceutical compositions and methods for using them
  申请人：Bascomb Newell

  公开号：US20080033027A1

  公开（公告）日：2008-02-07

  The invention provides preparations, formulations, kits and other products of manufacture (e.g., blister packs) comprising combinations of beneficial ingredients that are serviceable as therapies for improving states and disease symptoms such as involving inflammation, excessive sympathoneural drive, cachexia, anorexia, and anorexia-cachexia, as well as stress or anxiety related thereto, and methods of making and using them. The invention provides compositions and therapies comprising use of a beta adrenergic antagonist (also called “beta blockers”, e.g., propranolol) in combination with an anti-inflammatory agent, e.g., a nonsteroidal anti-inflammatory drug (NSAID), an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin receptor blocker (ARB), an anabolic steroid, a natural oil or fatty acid or any combination thereof.

  本发明提供了含有多种有益成分的制剂、配方、套装和其他制造产品（例如泡泡包装），这些组合可用作改善涉及炎症、过度交感神经驱动、消瘦、厌食和厌食-消瘦等状态和疾病症状的治疗，以及与之相关的压力或焦虑，以及制造和使用它们的方法。本发明提供了包括使用β肾上腺素受体拮抗剂（也称为“β受体阻滞剂”，例如普萘洛尔）与抗炎药物（例如非甾体抗炎药物（NSAID）、血管紧张素转化酶（ACE）抑制剂、血管紧张素受体拮抗剂（ARB）、合成类固醇、天然油脂或脂肪酸或其任意组合）的组合的组合物和治疗方法。